Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.